Takeda Pharmaceutical Company Limited - Depositary Receipt (Common Stock)
DE ˙ DB ˙ US8740602052
12,80 € ↓ -0,10 (-0,78%)
2026-06-04
DEL PRIS
SecurityDE:TKDA / Takeda Pharmaceutical Company Limited - Depositary Receipt (Common Stock)
InstitutionFirst Affirmative Financial Network
Latest Disclosed Ownership56,101 shares
Latest Disclosed Value $ 1,038,997
First Affirmative Financial Network reports 34.05% increase in ownership of TKDA / Takeda Pharmaceutical Company Limited - Depositary Receipt (Common Stock)

On May 11, 2026 - First Affirmative Financial Network filed a 13F-HR/A form disclosing ownership of 56,101 shares of Takeda Pharmaceutical Company Limited - Depositary Receipt (Common Stock) (DE:TKDA) valued at $886,396 USD as of March 31, 2026. The entity filed a previous 13F-HR on November 20, 2025 disclosing 41,852 shares of Takeda Pharmaceutical Company Limited - Depositary Receipt (Common Stock). This represents a change in shares of 34.05% during the quarter. The current value of the position is $718,093 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-11 2026-03-31 13F/A-1 TAKEDA PHARMACEUTICAL SPONSORED ADS 874060205 56,101 14,249 34.05 1,039 69.61 0.4031
2026-05-08 2026-03-31 13F TAKEDA PHARMACEUTICAL SPONSORED ADS 874060205 41,852 0 613 0.2883
2025-11-20 2025-09-30 13F TAKEDA PHARMACEUTICAL SPONSORED ADS 874060205 41,852 6,025 16.82 613 10.67 0.2883
2025-11-20 2025-06-30 13F TAKEDA PHARMACEUTICAL SPONSORED ADS 874060205 35,827 7,961 28.57 554 33.57 0.2847
2025-04-11 2025-03-31 13F TAKEDA PHARMACEUTICAL SPONSORED ADS 874060205 27,866 7,264 35.26 414 52.21 0.2539
2025-01-23 2024-12-31 13F TAKEDA PHARMACEUTICAL SPONSORED ADS 874060205 20,602 4,736 29.85 273 20.89 0.1574
2024-10-10 2024-09-30 13F TAKEDA PHARMACEUTICAL SPONSORED ADS 874060205 15,866 15,866 226 0.1235
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.